Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in
treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled
monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them
without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective
treatment for colorectal cancer